ARIAD PHARMACEUTICALS INC Cashflow Statement

Ask AI

Overview Financial Statements SEC Filings Executives News Red Flags Capital Raising Ownership Insider Transactions Congressional Trades

Financial Statements

Income Statement Balance Sheet Cashflow Statement

Consolidated statements of cash flows

In millions of USD, except per-share amounts

	FY2015 12 months to Dec 31, 2015	FY2014 12 months to Dec 31, 2014	FY2013 12 months to Dec 31, 2013	FY2012 12 months to Dec 31, 2012	FY2011 12 months to Dec 31, 2011
Cash flows from operating activities:
Net loss
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation, amortization and impairments
Depreciation, amortization and impairment charges
Stock-based compensation
Deferred executive compensation expense
Benefit from intraperiod tax allocation
Gain on disposition of stock
Revaluation of warrant liability
Repayment of interest related to facility lease obligation
Increase (decrease) from:
Accounts receivable
Inventory
Other current assets
Other assets
Amounts due under license and collaboration agreements
Accounts payable
Accrued compensation and benefits
Accrued product development expenses
Other accrued expenses
Other liabilities
Deferred revenue
Deferred executive compensation paid

Net cash used in operating activities
Cash flows from investing activities:
Acquisitions of marketable securities
Proceeds from maturities of marketable securities
Change in restricted cash
Investment in property and equipment
Gain on disposition of stock
Investment in intangible assets
Proceeds from long-term borrowings
Proceeds from disposition of stock
Net cash provided by (used in) investing activities

Cash flows from financing activities:
Proceeds from royalty financing
Royalty financing fees paid
Proceeds from issuance of convertible debt, including equity component
Convertible debt fees paid
Proceeds from issuance of warrants
Purchase of convertible bond hedges
Repayment of long-term debt
Principal payments under capital lease obligations
Reimbursements of amounts related to facility lease obligation
Proceeds from issuance of common stock pursuant to warrants
Proceeds from issuance of common stock pursuant to stock option and purchase plans
Payment of tax withholding obligations related to stock compensation
Net cash provided by financing activities

Effect of exchange rates on cash
Net increase (decrease) in cash and cash equivalents
Cash and cash equivalents, beginning of year
Cash and cash equivalents, end of year
Supplemental disclosures:
Interest paid
Income taxes paid
Capitalization of construction-in-progress related to facility lease obligation
Non-cash transaction - property and equipment included in accounts payable or accruals
Non-cash transaction - marketable equity securities recorded at fair market value

Comments